Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.68 |
| ▸ | CES1 | P23141 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28670034 | 0.90 | MAPT (0.71) | CES2CES1MAPTLMNASMN1; SMN2 | |
| SCHEMBL13043540 | 0.83 | CES2 (0.71) | CES2CES1MAPTALDH1A1LMNA | |
| SCHEMBL167254 | 0.82 | CES2 (1.00) | CES2CES1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2401025 | 0.81 | MAPT (0.61) | CES2CES1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL18998428 | 0.81 | CES2 (0.68) | CES2CES1MAPTALDH1A1LMNA | |
| SCHEMBL5852775 | 0.81 | MAPT (0.61) | CES2CES1MAPTLMNATHRA | |
| SCHEMBL6272776 | 0.81 | MAPT (0.61) | CES2CES1MAPTLMNASMN1; SMN2 | |
| SCHEMBL5949776 | 0.80 | CES2 (0.75) | CES2CES1MAPTALDH1A1LMNA | |
| SCHEMBL3629096 | 0.80 | CES2 (0.75) | CES2CES1MAPTALDH1A1LMNA | |
| SCHEMBL23190953 | 0.79 | MAPT (0.59) | CES2CES1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390754-A1 | METHODS OF ADMINISTERING TOLPERISONE | NEURANA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | claimed |
| CN-111886007-A | Methods of administering tolperisone | 纽兰娜制药股份有限公司 | 2020-11-03 | — | — | CN | claimed |
| EP-3709989-A1 | METHODS OF ADMINISTERING TOLPERISONE | Neurana Pharmaceuticals, Inc. (US) | 2020-09-23 | — | — | EP | claimed |
| US-20180344717-A1 | COMPOSITIONS OF TOLPERISONE | Sanochemia Pharmazeutika GmbH (AT) | 2018-12-06 | — | — | US | claimed |
| US-20170239228-A1 | COMPOSITIONS OF TOLPERISONE | Sanochemia Pharmazeutika GmbH (AT) | 2017-08-24 | — | — | US | claimed |
| US-9675598-B2 | Compositions of tolperisone | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2017-06-13 | — | — | US | claimed |
| US-9662317-B2 | Methods of administering tolperisone for therapeutic purposes | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2017-05-30 | — | — | US | claimed |
| US-20160367540-A1 | COMPOSITIONS OF TOLPERISONE | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2016-12-22 | — | — | US | claimed |
| US-20160220549-A1 | METHODS OF ADMINISTERING TOLPERISONE FOR THERAPEUTIC PURPOSES | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2016-08-04 | — | — | US | claimed |
| EP-2150540-B1 | METHOD FOR THE PRODUCTION OF HIGHLY PURE 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND AGENT FORMULATIONS CONTAINING TOLPERISONE | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2016-06-01 | — | — | EP | claimed |
| US-9315480-B2 | Compositions of tolperisone | SANOCHEMIA PHARMAZEUTIKA AG (AU) | 2016-04-19 | — | — | US | claimed |
| US-8785100-B2 | Two-component developer | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2014-07-22 | — | — | US | claimed |
| US-20130189612-A1 | TWO-COMPONENT DEVELOPER | KONICA MINOLTA BUSINESS TECHNOLOGIES, INC. (JP) | 2013-07-25 | — | — | US | claimed |
| US-20100150995-A1 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2010-06-17 | — | — | US | claimed |
| JP-54044627-A | — | — | None | — | — | JP | disclosed |
| JP-54128539-A | — | — | None | — | — | JP | disclosed |
| CN-110845443-B | Method for preparing high-purity tolperisone hydrochloride | 嘉实（湖南）医药科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| JP-S54128539-A | PREPARATION OF ACRYLOPHENONE DERIVATIVE | ASAHI CHEM IND CO LTD | 1979-10-05 | — | — | JP | disclosed |
| JP-S5444627-A | PRODUCTION OF ACRYLIC ACID DERIVATIVE | ASAHI CHEM IND CO LTD | 1979-04-09 | — | — | JP | disclosed |
| US-4013620-A | OXIDATION RESISTANCE | AMERICAN CYANAMID COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390754-A1 | METHODS OF ADMINISTERING TOLPERISONE | ACHE, THOP1, CHAT | CES2 588/4885CES1 216/4885MAPT 868/4885 |
| US-20100150995-A1 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE | MMP17, MMP25, MMP1 | CES2 913/4885CES1 633/4885MAPT 175/4885 |
| US-20160220549-A1 | METHODS OF ADMINISTERING TOLPERISONE FOR THERAPEUTIC PURPOSES | THOP1, ADAMTS4, ADAMTS5 | CES2 63/4885CES1 452/4885MAPT 2978/4885 |
| US-20170239228-A1 | COMPOSITIONS OF TOLPERISONE | ADAMTS4, ADAMTS1, ADAMTS5 | CES2 681/4885CES1 484/4885MAPT 1586/4885 |
| US-20160367540-A1 | COMPOSITIONS OF TOLPERISONE | ADAMTS4, ADAMTS1, ADAMTS5 | CES2 681/4885CES1 484/4885MAPT 1586/4885 |
| US-20180344717-A1 | COMPOSITIONS OF TOLPERISONE | ADAMTS4, ADAMTS1, ADAMTS5 | CES2 681/4885CES1 484/4885MAPT 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.